ReviewTranslational lung cancer research2026

Utility of various programmed death-ligand 1 (PD-L1) assays in predicting the clinical benefit of immune checkpoint inhibitors in PD-L1-expressing non-small-cell lung cancer patients: a systematic review.

Ross A Soo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.